A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis

Learn more about:
Related Clinical Trial
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis Evaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis Study Of The Long Term Outcome Of Tuberculous Meningitis In Vietnamese Adults Treated With Adjunctive Dexamethasone Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis

Brief Title

A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis

Official Title

A Pilot Phase II Randomized Controlled Double Blind Trial of 81mg Aspirin Daily vs. 1000 mg Aspirin Daily vs. Placebo as Adjunctive Therapy in HIV Negative Adults With Tuberculous Meningitis

Brief Summary

      Tuberculous meningitis is a severe brain infection which often causes disability and death
      even when treated with the best available treatment. Aspirin is a type of anti-inflammation
      drug which can reduce the inflammatory response in brains of patients with tuberculous
      meningitis, and therefore may decrease some of the most severe outcomes. This study compares
      the use of aspirin (at 2 different doses) versus placebo as an additional therapy to the
      standard treatment to see if aspirin is safe and helpful in reducing disability and death
      from tuberculous meningitis. Patients will be treated with aspirin or placebo for 60 days and
      followed up while on standard treatment for 8 months.

Detailed Description

      The study is a parallel group, double blind, randomised, placebo controlled trial of 60 days
      treatment with placebo vs. 81mg daily dose vs. 1000mg daily dose aspirin for the treatment of
      HIV-uninfected adults with tuberculous meningitis.

      All patients will receive standard anti-tuberculous chemotherapy and adjunctive
      dexamethasone, according to Viet Nam National Tuberculosis Programme guidelines. Participants
      will be stratified by Medical Research Council UK disease severity grade, and randomized at
      enrollment to one of three study arms (1:1:1 ratio). Patients will be admitted to hospital
      for at least the first 14 days of study treatment enabling real-time active surveillance of
      any adverse events after which they will be discharged according to clinical care with
      continued monitoring.

      A schedule of clinical and laboratory monitoring including lumbar puncture, pharmacokinetic
      assessment of peripheral blood monocyte/macrophage antimicrobial activity, clinical
      assessments, brain magnetic resonance imaging (MRI) and neurological assessment will manage
      patient safety and capture study outcomes.

Study Phase

Phase 2

Study Type


Primary Outcome

Number of episodes of either cerebral bleeding or clinically significant upper-gastro-intestinal bleeding (composite endpoint)

Secondary Outcome

 Time to death


Tuberculous Meningitis


81mg aspirin

Study Arms / Comparison Groups

 81mg aspirin
Description:  Aspirin 81mg daily for 60 days


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

October 17, 2014

Completion Date

December 22, 2016

Primary Completion Date

June 24, 2016

Eligibility Criteria

        Inclusion Criteria:

          -  Male or female, aged 18 years or above.

          -  Suspected TBM and anti-tuberculosis chemotherapy either planned or started

          -  Less than 3 days of anti-tuberculosis chemotherapy taken for the current infection

          -  Patient or representative (if the patient is unable) is willing and able to give
             informed consent for participation in the study.

        Exclusion Criteria:

          -  HIV infection (negative rapid test or Elisa test is required)

          -  Unlikely, for any reason, to be able to have an MRI brain scan within 5 days (120
             hours) of randomisation

          -  Known or suspected infection with multi-drug resistant tuberculosis (resistant to at
             least isoniazid and rifampicin)

          -  Unable to take isoniazid, rifampicin, or pyrazinamide at recommended doses for any

          -  History of diagnosed peptic ulceration or gastro-intestinal bleeding

          -  Active gastro-intestinal bleeding is suspected

          -  Taken >1 dose of aspirin (at any dose) or any other non-steroidal anti-inflammatory
             drugs for any reason within 2 weeks of screening

          -  Aspirin considered mandatory for any reason by the attending physician

          -  Aspirin considered to be contraindicated for any reason by the attending physician

          -  Pregnancy or breast feeding (negative urine pregnancy test for all females of
             child-bearing age)

          -  Dexamethasone considered to be contraindicated for any reason by the attending

          -  Any other significant disease or disorder which, in the opinion of the investigator,
             may either put the participants at risk because of participation in the study, or may
             influence the result of the study, or the participant's ability to participate in the




18 Years - N/A

Accepts Healthy Volunteers



Guy Thwaites, MD, PhD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Oxford University Clinical Research Unit, Vietnam


 Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

Study Sponsor

Guy Thwaites, MD, PhD, Principal Investigator, Oxford University of Clinical Research

Verification Date

March 2017